Most S&P 500 companies write rules to stop employees from using confidential information to trade other businesses’ stock, but some are now thinking about scaling back their bans to avoid exposing their executives to new legal troubles.
That’s perhaps one unintended consequence for the Securities and Exchange Commission following its win in the first-ever trial over “shadow trading,” some lawyers say.
A key part of the SEC’s case against a former biopharma executive, Matthew Panuwat, was that his company’s policies prohibited him from buying any public company’s stock based on his insider knowledge about his own employer’s pending deal.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.